This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Lozano-Ortega G, Machuk RW, Hass HE, Barbeau M, Mathen MK.The cost-effectiveness of ranibizumab compared to PDT-V and BSC for the treatment of age-related macular degeneration in Canada. Value in Health 11: A286, No. 3, May-Jun 2008
Bueno RLP, Lion E.Cost-effectiveness of anti VEGF therapies for wet age-related macular degeneration in Brazil: the private payer perspective. Value in Health 11: A287, No. 3, May-Jun 2008
Patel JJ, Stull MA, Bounthavong M, Christopher MLD, Foster E, Morreale AP, Plowman BK, Boggie DT.Cost-effectiveness analysis of bevacizumab and ranibizumab in neovascular age-related macular degeneration: a clinical and economic comparison of two vascular endothelial growth factor inhibitor treatments. Value in Health 11: A288, No. 3, May-Jun 2008
Turpcu A, Hay JW.The cost-effectiveness of ranibizumab (Lucentis Rm) in treating patients with predominantly classic, minimally classic, and occult neovascular age-related macular degeneration. Value in Health 11: A288-A289, No. 3, May-Jun 2008
Lu LY, McGhan W.Cost-effective analysis of pegaptanib (Macugen Rm) as compared with ranibizumab (Lucentis Rm) for treating in age-related macular degeneration. Value in Health 11: A288, No. 3, May-Jun 2008
Rights and permissions
About this article
Cite this article
AMD news from ISPOR. Pharmacoecon. Outcomes News 555, 3 (2008). https://doi.org/10.2165/00151234-200805550-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200805550-00003